| Code | CSB-RA004847MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Lanerkitug, targeting the C-C chemokine receptor type 8 (CCR8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a critical role in immune cell trafficking and tissue localization. The receptor is particularly enriched on tumor-infiltrating Tregs in various malignancies, where it contributes to the immunosuppressive tumor microenvironment by facilitating Treg accumulation and retention within tumors.
Lanerkitug is an investigational therapeutic antibody that selectively depletes CCR8-positive Tregs through antibody-dependent cellular cytotoxicity, aiming to enhance anti-tumor immunity while preserving peripheral Treg populations. This biosimilar provides researchers with a valuable tool for studying CCR8-mediated immune regulation, Treg biology, and tumor immunology. It supports investigations into cancer immunotherapy mechanisms, autoimmune disease pathogenesis, and inflammatory processes where CCR8-expressing cells play pivotal roles.
There are currently no reviews for this product.